SLIDE SETS

Explore slide sets below.

Prescribing information for DOVATO (dolutegravir/lamivudine) can be found here.
Prescribing information for VOCABRIA (cabotegravir) + REKAMBYS (rilpivirine) can be found here.

Results:

Showing results for

VOCABRIA + REKAMBYS

6-month outcomes from German CARLOS cohort

DOVATO

View the presentation detailing long term data for Dovato from TANGO 196 weeks and URBAN real world study.

DOVATO

View the presentation showing data on Dovato vs BIC/F/TAF and DTG 3DRs from IDWeek and Glasgow 2022.

PM-GB-HVX-WCNT-220003 | March 2024

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.